简体
  • 简体中文
  • 繁体中文

热门资讯> 正文

4D分子治疗学称4D-710囊性纤维化肺病1期AEROW试验的中期数据显示有意义的肺功能活动

2025-12-17 20:03

  • Clinically meaningful lung function activity, measured by ppFEV1 and LCI2.5, with follow-up through 1 year at dose selected for Phase 2 
  • Durable CFTR transgene expression within target therapeutic range with follow-up through at least 1 year
  • Data support 4D-710's potential to be a durable, redosable, variant-agnostic, disease-modifying treatment for people with cystic fibrosis lung disease with high unmet need

风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。